Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab fatigue and quality-of-life study in relapsing multiple sclerosis
ISRCTN55332718Phase 4Completed
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Trait fatigue by FSMC total score over 24 months. Started Dec 2021; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN55332718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55332718.